Business
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and se...
About this update from Profound Medical Corp
[{"type":"text","content":"Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®\nMount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce the world-renowned Mount Sinai Hospital has successfully treated its first prostate cancer patient with the TULSA-PRO® system. The TULSA Procedure™ represents a major advancement in prostate care, and is used by physicians to treat prostate cancer and benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to ‘kill temperature’ (55-57°C), while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction. Michael Palese, MD, Chair, Department of Urology, Mount Sinai Downtown and Professor, Department of Urology at the Icahn School of Medicine at Mount Sinai; Neil Rofsky, MD, MHA, Dr. Charles and Marilyn Newman Professor and Chair of Diagnostic, Molecular and Interventional Radiology at the Mount Sinai Health System; Kyrollis Attalla, MD, Assistant Professor, Department of Urology and Christine Chen, MD, Associate Professor, Diagnostic, Molecular and Interventional Radiology, recently collaborated to perform the health system’s first TULSA Procedure, with the patient responding well to the treatment and being discharged the same day. “With this milestone, M...